Meta-Analysis
Copyright ©The Author(s) 2015.
World J Gastroenterol. May 21, 2015; 21(19): 6044-6051
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.6044
Table 1 Baseline characteristics of the included studies
StudyAge (yr)Drug and doseCaseSeverityTreatmentDuration (wk)
ACT 141.4 ± 13.7Placebo121Moderate to-severe active UCIntravenous infusions at weeks 0, 2 and 6 and then every eight weeks or matching placebo54
(Rutgeerts et al[16], Feagan et al[17], Sandborn et al[18])42.4 ± 14.3Infliximab 5 mg/kg121
41.8 ± 14.9Infliximab 10 mg/kg122
ACT 239.3 ± 13.5Placebo123Moderate-to-severe active UCIntravenous infusions at weeks 0, 2 and 6 and then every eight weeks or matching placebo30
(Rutgeerts et al[16], Feagan et al[17], Sandborn et al[18])40.5 ± 13.1Infliximab 5 mg/kg121
40.3 ± 13.3Infliximab 10 mg/kg120
Suzuki et al[19]41.3 ± 13.6Placebo96Moderate-to-severe active UCSubcutaneous injections 160/80 mg at week 0, 80/40 mg at week 2 and then 40 mg beginning at week 4 every other week or matching placebo52
44.4 ± 15.0Adalimumab 80/40 mg87
42.5 ± 14.6Adalimumab 160/80 mg90
ULTRA 241.3 ± 13.2Placebo246Moderate-to-severe active UCSubcutaneous injections 160 mg at week 0, 80 mg at week 2 and then 40 mg beginning at week 4 every other week or matching placebo52
(Sandborn et al[20])39.6 ± 12.5Adalimumab2488
Reinisch et al[21]37.0 ± 9.0Placebo130Moderate-to-severe active UCSubcutaneous injections 160/80 mg at week 0, 80/40 mg at week 2 and then 40 mg beginning at week 4 every other week or matching placebo
40.0 ± 9.5Adalimumab 80/40 mg130
36.5 ± 9.5Adalimumab 160/80 mg1306
PURSUIT-SC39.0 ± 13.0Placebo331Moderate-to-severe active UCSubcutaneous injections 400/200 mg at week 0 and 200/100 at week 2 or matching placebo
(Sandborn et al[12])40.0 ± 13.5Golimumab 200/100 mg331
40.7 ± 13.7Golimumab 400/200 mg33154
PURSUIT-M40.2 ± 14.1Placebo156Moderate-to-severe active UCSubcutaneous injections 100/50 mg every 4 wk or matching placebo
(Sandborn et al[13])41.4 ± 13.8Golimumab 50 mg154
39.1 ± 13.1Golimumab 100 mg15452
GEMINI 141.2 ± 12.5Placebo149Moderate-to-severe active UCIntravenous infusions every 4 wk or every 8 wk or matching placebo
(Feagan et al[9,14])40.1 ± 13.2Vedolizumab 300 mg746